CBIO
NASDAQ HealthcareCrescent Biopharma, Inc. - Common Stock
Biotechnology
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.
๐ Market Data
| Price | $15.11 |
|---|---|
| Volume | 857,477 |
| Market Cap | 416.66M |
| RSI (14-Day) | 36.7 |
| 200-Day MA | $14.65 |
| 50-Day MA | $18.16 |
| 52-Week High | $27.41 |
| 52-Week Low | $8.72 |
| Forward P/E | -5.08 |
| Price / Book | 2.79 |
๐ฏ Investment Strategy Scores
CBIO scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ช Falling Knife (78/100) โ this strategy Contrarian plays (oversold + below moving average).
Lowest fit among scored strategies: ๐ Institutional Whale (10/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find CBIO in your text
Paste any article, transcript, or post โ the tool will extract CBIO and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-07-16.